Treatment with MK-6482 appeared to be well tolerated and induced clinical responses among patients with von Hippel-Lindau disease (VHL)–associated renal cell carcinoma (RCC), according to study findings presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.
The trial showed an objective response rate (ORR) in RCC tumors per RECIST by independent review of 27.9%. Moreover, 8 patients who had an unconfirmed response showed an ORR of 41.0%. Additionally, 86.9% of patients had a decrease in the size of their target lesions and median time to response was 5.5 months.
Eric Jonasch, MD, professor of genitourinary medical oncology at The University of Texas MD Anderson Cancer Center, spoke to CancerNetwork about the results of the trial.
So, VHL disease at this time does not have an FDA approved therapy. It’s a hereditary…